IMpower133: patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Kazarnowicz, A | |
dc.contributor.author | Karaseva, N | |
dc.contributor.author | Sanchez, A | |
dc.contributor.author | Liu, V | |
dc.contributor.author | Horn, L | |
dc.contributor.author | Quach, C | |
dc.contributor.author | Yu, W | |
dc.contributor.author | Kabbinavar, F | |
dc.contributor.author | Lam, S | |
dc.contributor.author | Mansfield, A | |
dc.date.accessioned | 2019-03-29T14:22:30Z | |
dc.date.available | 2019-03-29T14:22:30Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Califano R, Ka?arnowicz A, Karaseva N, Sánchez A, Liu SV, Horn L, et al. IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2018;29(suppl_10):17. | en |
dc.identifier.doi | 10.1093/anonc/mdy486 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621658 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/anonc/mdy486 | en |
dc.title | IMpower133: patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | King's College, London, London, United Kingdom | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] |